At a press conference at ESMO 2014, Dr Robert presents the results of a phase III trial which found that targeting BRAF V600E/K mutation-positive melanoma with a combination of dabrafenib plus trametinib achieved longer overall survival and progression-free survival as well as better response rates, compared to treatment with vemurafenib alone.

Read the news story for more.